
Research Article Volume 01, Issue No. 02. 2024

The National Medical Journal of Health Science



Association of SARS-CoV-2 Vaccination or Infection With Bell Palsy

[1] Maria Theresa, [1] Reynanta

[1] Faculty of Medicine, North Sumatera University, Medan City, North Sumatera, Indonesia

Correspondence : dr.mariatheresa9283@gmail.com

Article History :
Received date : 2024/10/12
Revised date : 2024/11/17
Accepted date : 2024/12/28
Published date : 2025/01/02

Copyright: *© 2024 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (BY NC) license (https://creativecommons.org/licenses/by-nc/4.0/).*

ABSTRACT

Background: The reviewed literature provides a comprehensive examination of the relationship between SARS-CoV-2 infection, vaccination, and the incidence of Bell's palsy. Initial studies, such as that by (Mutlu et al., 2021), found no significant increase in Bell's palsy cases during the pandemic, despite the virus's neuroinvasive potential. This finding challenges assumptions of a direct correlation between COVID-19 and Bell's palsy, emphasizing the need for caution in interpreting such associations. **Literature Review:** The literature also indicates that while there are isolated cases of Bell's palsy associated with COVID-19, overall prevalence remains low. For example, (Bhola et al., 2022) reported a mere 0.08% incidence among COVID-19 patients. This statistic suggests that while some individuals may experience Bell's palsy post-infection, the risk is minimal for the general population. Case studies, such as the one conducted by (C. Mussatto et al., 2022), reinforced the importance of diagnostic accuracy in attributing Bell's palsy to vaccination. The authors emphasized that the prognosis for Bell's palsy is generally favorable, further supporting the notion that vaccination benefits outweigh potential risks. The most recent findings presented by (Young Kwak et al., 2024) illustrated an increase in the age of diagnosis for Bell's palsy post-COVID-19, suggesting that older individuals may be at greater risk. This study also raised questions about the immune response triggered by mRNA vaccines and its potential role in facial nerve damage. **Conclusion:** In conclusion, the literature reveals a complex interplay between SARS-CoV-2 infection, vaccination, and the incidence of Bell's palsy. While some studies indicate a potential association, the overall risk appears minimal, with the benefits of vaccination significantly outweighing the risks. Ongoing research is essential to clarify these relationships and the underlying mechanisms involved.

Keywords: SARS-CoV-2 Vaccination, Infection, Bell Palsy

Downloaded from The National Medical Journal of Health Science
Copyright © International Medical Journal Corp. Ltd. All rights reserved

INTRODUCTION

The association between SARS-CoV-2 and Bell's palsy has garnered significant attention in recent literature, particularly in light of the ongoing pandemic and the rollout of COVID-19 vaccinations. The initial exploration of this topic can be traced back to the work of (Mutlu et al., 2021), who examined whether the pandemic increased the incidence of Bell's palsy. Their findings indicated no significant rise in cases during the pandemic, despite the neuroinvasive potential of SARS-CoV-2, which shares similarities with other coronaviruses known to affect the nervous system. This study laid the groundwork for further investigation into the neurological implications of COVID-19.

Following this, (K. Szewczyk et al., 2021) presented a case report highlighting bilateral facial palsy as a potential isolated symptom of COVID-19 infection. They acknowledged the link between Guillain-Barré syndrome and SARS-CoV-2, emphasizing the need for awareness of possible adverse events related to COVID-19 vaccinations, including Bell's palsy. Their analysis underscored the importance of understanding the immune-mediated mechanisms at play rather than attributing neurological complications directly to the virus.

In the same year, (Shibli et al., 2021) conducted a population-based study to investigate the association between the BNT162b2 mRNA COVID-19 vaccine and Bell's palsy. While they noted a higher incidence of Bell's palsy in vaccine groups compared to placebos, the authors concluded that the numbers were too small to establish a causal relationship. Their findings were corroborated by other studies, which also found conflicting evidence regarding the risk of Bell's palsy post-vaccination.

(Bhola et al., 2022) further detailed the prevalence of Bell's palsy among COVID-19 patients, reporting a low incidence rate but acknowledging its occurrence in some cases. Their work contributed to the understanding of the

Downloaded from The National Medical Journal of Health Science
Copyright © International Medical Journal Corp. Ltd. All rights reserved

neurological toll of COVID-19, suggesting that while the virus may be linked to Bell's palsy, the exact mechanisms remain to be fully elucidated.

(C. Mussatto et al., 2022) focused on a specific case of Bell's palsy following COVID-19 vaccination in an HIV-positive patient. Their case highlighted the importance of diagnostic certainty in attributing Bell's palsy to vaccination, while also noting the conflicting evidence in the literature regarding the risk associated with COVID-19 vaccines. They called for further research to clarify the potential link and emphasized the generally benign prognosis of Bell's palsy.

(Ayman Haykal & L. Menkes, 2022) reviewed existing literature on the neurophysiological implications of COVID-19, noting that while some studies found no significant association between vaccination and Bell's palsy, the topic remains controversial. They highlighted the need for electrodiagnostic assessments to better understand the nuances of Bell's palsy in the context of SARS-CoV-2.

Most recently, (Young Kwak et al., 2024) conducted a multicenter retrospective study that examined the impact of the COVID-19 pandemic on the incidence of Bell's palsy and Ramsay-Hunt syndrome. Their findings suggested an increase in the age of diagnosis for Bell's palsy post-COVID-19 and raised questions about the type I interferon response triggered by mRNA vaccines as a potential mechanism for the observed cases. They emphasized the necessity of investigating the direct effects of SARS-CoV-2 on facial nerve damage and the role of co-infections in recovery outcomes.

Collectively, these studies illustrate a complex interplay between SARS-CoV-2 infection, vaccination, and the incidence of Bell's palsy, highlighting the need for ongoing research to clarify these associations and their underlying mechanisms.

LITERATURE REVIEW

Downloaded from The National Medical Journal of Health Science
Copyright © International Medical Journal Corp. Ltd. All rights reserved

The article "Does the SARS-CoV-2 pandemic really increase the frequency of peripheral facial palsy?" by (Mutlu et al., 2021) provides a critical examination of the incidence of Bell's palsy in the context of the COVID-19 pandemic. The authors aimed to investigate whether there was a notable increase in the frequency of this condition during the pandemic period, ultimately concluding that no significant difference was observed.

The study contextualizes the discussion of Bell's palsy within the broader implications of SARS-CoV-2, highlighting its similarities to other coronaviruses such as SARS-CoV and MERS-CoV. The authors reference existing literature that indicates these viruses may have neuroinvasive potential, leading to neurological complications. For instance, they mention research by Mao et al. that identified central nervous system involvement in severe COVID-19 cases, as well as Zhou et al.'s findings on the relationship between SARS-CoV-2 and viral encephalitis. This background sets the stage for exploring the potential link between SARS-CoV-2 infections and the onset of peripheral facial nerve palsy.

(Mutlu et al., 2021) also address the historical association of viral agents, particularly Herpes Simplex Virus-1 and Varicella Zoster Virus, with idiopathic peripheral facial nerve palsy. The authors note that during the pandemic, instances of peripheral facial paralysis, coupled with positive RT-PCR test results for SARS-CoV-2, raised concerns about a possible causal relationship. This observation has prompted various publications discussing the potential implications of COVID-19 on neurological health.

However, the article's main finding—that there is no significant increase in the incidence of Bell's palsy during the pandemic—challenges some of the prevailing narratives that suggest a direct association between SARS-CoV-2 infection and the development of this condition. This conclusion is crucial for clinicians and public health officials, as it underscores the importance of differentiating between correlation and causation in the context of emerging infectious diseases.

Downloaded from The National Medical Journal of Health Science
Copyright © International Medical Journal Corp. Ltd. All rights reserved

The article "Facial Diplegia—Complication or Manifestation of SARS-CoV-2 Infection? A Case Report and Systemic Literature Review" by (K. Szewczyk et al., 2021) provides a comprehensive examination of the neurological complications associated with SARS-CoV-2 infection, particularly focusing on bilateral facial palsy and its potential relationship with Guillain-Barré Syndrome (GBS). The authors present several cases where patients exhibited facial diplegia as an isolated symptom of COVID-19, highlighting the complexity of the condition and its manifestations.

A critical evaluation of the material reveals that the article effectively synthesizes existing literature while presenting new case studies that contribute to the understanding of neurological complications arising from COVID-19. The authors argue that GBS, a well-documented neurological disorder, may be triggered by SARS-CoV-2, thereby expanding the list of potential etiological factors for this syndrome. This assertion is particularly noteworthy given the increasing recognition of viral infections as potential triggers for GBS ((K. Szewczyk et al., 2021)). The favorable outcomes reported in the cases, ranging from slight to nearly complete recovery, provide a hopeful perspective on the prognosis for patients experiencing such complications.

Moreover, the authors emphasize the importance of awareness among medical professionals regarding the potential adverse effects of COVID-19 vaccinations, including Bell’s palsy and GBS-like symptoms. This acknowledgment is essential, as it underscores the need for a balanced view of vaccination benefits versus risks. The authors conclude that, despite the potential for these complications, the overall benefits of vaccination against COVID-19 significantly outweigh the risks, a position that aligns with broader public health recommendations.

The article also points to an important gap in the current understanding of the etiopathogenesis of these neurological manifestations. The authors suggest that an immune-mediated reaction rather than direct viral damage may be responsible, thus calling for further research to elucidate the underlying mechanisms. This is a

Downloaded from The National Medical Journal of Health Science
Copyright © International Medical Journal Corp. Ltd. All rights reserved

critical area for future investigation, as understanding the pathophysiology could lead to improved management strategies for affected patients.

The article titled "Association between vaccination with the BNT162b2 mRNA COVID-19 vaccine and Bell's palsy: a population-based study" by (Shibli et al., 2021) provides a critical examination of the potential association between the BNT162b2 mRNA COVID-19 vaccine and the incidence of Bell's palsy. The authors begin by contextualizing the safety data derived from pre-licensure trials for both Pfizer-BioNTech and Moderna vaccines, which indicated a higher incidence of Bell's palsy among vaccinated individuals compared to those receiving a placebo. However, they emphasize that the number of cases reported was small, thereby rendering any conclusions about a causal relationship between the vaccine and Bell's palsy inconclusive.

The article further discusses post-authorization surveillance, highlighting case reports that emerged after the emergency use authorization of the vaccines, which noted instances of Bell's palsy occurring after vaccination. Despite these reports, the authors reference a small hospital-based case-control study conducted in Israel that found no significant association between the BNT162b2 vaccine and the onset of Bell's palsy. This finding is crucial as it suggests that the initial concerns raised during the pre-licensure trials may not be substantiated by subsequent real-world data.

Moreover, the article incorporates findings from a recent population-based case-control study in Hong Kong, which indicated an increased risk of Bell's palsy following the CoronaVac vaccine, but again found no such association with the BNT162b2 vaccine. This distinction is particularly important in the discourse surrounding vaccine safety, as it underscores the variability in outcomes associated with different vaccine types.

The article "Neurological toll of COVID-19" by (Bhola et al., 2022) provides a thorough examination of the association between SARS-CoV-2 infection and Bell's palsy, a condition characterized by sudden-onset peripheral facial nerve

Downloaded from The National Medical Journal of Health Science
Copyright © International Medical Journal Corp. Ltd. All rights reserved

palsy. The authors highlight that while Bell's palsy has been reported in some COVID-19 patients, the prevalence is notably low, with a documented incidence of 0.08% among infected individuals. This statistic is particularly significant as it suggests that while there may be a potential link between the virus and the onset of Bell's palsy, the overall risk remains minimal for the general population.

The article further explores the recurrence rate of Bell's palsy in patients with a prior diagnosis, which stands at 8.6%. This finding raises important questions about the underlying mechanisms that may predispose certain individuals to develop Bell's palsy following a COVID-19 infection. The authors propose that the pathophysiological processes involved may be similar to those observed in other neurological disorders, such as cerebrovascular disease (CVD) and acute ischemic stroke (AIS). However, the absence of SARS-CoV-2 RNA in cerebrospinal fluid samples from reported cases indicates that the virus may not directly invade the nervous system, necessitating further investigation into alternative mechanisms, such as inflammatory responses or autoimmune reactions triggered by the infection.

A case report mentioned in the article illustrates the clinical presentation of Bell's palsy in a COVID-19 patient, describing the development of left-sided facial weakness accompanied by retro-auricular pain and dysgeusia. This anecdotal evidence underscores the need for a more detailed understanding of how COVID-19 may influence neurological health, particularly in patients with pre-existing vulnerabilities.

The article titled "Bell's palsy following COVID-19 vaccine administration in HIV+ patient" by (C. Mussatto et al., 2022) provides a detailed case study that emphasizes the importance of diagnostic certainty when evaluating the potential association between COVID-19 vaccination and Bell's palsy. The authors begin by outlining the clinical characteristics of Bell's palsy, which is defined as a peripheral facial nerve weakness that manifests acutely, reaching maximal weakness within 24 to 72 hours. They note that the prognosis for patients diagnosed with Bell's palsy is generally favorable, with most individuals regaining full function within weeks to months.

Downloaded from The National Medical Journal of Health Science
Copyright © International Medical Journal Corp. Ltd. All rights reserved

In the context of their patient, the authors assert that the clinical presentation was consistent with typical Bell's palsy symptoms, supported by a thorough clinical history, physical examination, and laboratory tests that ruled out alternative diagnoses. This careful diagnostic approach reinforces the need for accuracy in identifying Bell's palsy, particularly when assessing its potential occurrence following vaccination.

The article also reviews data from phase 3 clinical trials for COVID-19 vaccines, which reported seven cases of Bell's palsy—four associated with the Pfizer/BioNTech BNT162b2 vaccine and three with the Moderna mRNA-1273 vaccine. Notably, the control groups did not report any cases. This discrepancy raises questions about the relationship between the vaccines and the incidence of Bell's palsy; however, the authors highlight the conflicting nature of existing research. Some studies indicate an increased incidence of Bell's palsy post-vaccination, while others find no significant association.

(C. Mussatto et al., 2022) emphasize the necessity of ongoing surveillance for Bell's palsy symptoms in the 60 days following vaccination, as recommended by the FDA. However, they conclude that the overall risk of developing Bell's palsy post-vaccination is minimal compared to the substantial benefits of COVID-19 vaccination. This assertion is critical as it situates the discussion within the broader context of public health, balancing potential risks against the imperative need for vaccination in combating the COVID-19 pandemic.

The article titled "The clinical neurophysiology of COVID-19-direct infection, long-term sequelae and para-immunization responses: A literature review" by (Ayman Haykal & L. Menkes, 2022) provides a comprehensive examination of the neurological implications associated with COVID-19, specifically focusing on the occurrence of Bell's palsy. The authors critically analyze existing literature, including a review of 20 cases where Bell's palsy emerged as a notable neurological manifestation in COVID-19 positive patients shortly after infection.

Downloaded from The National Medical Journal of Health Science
Copyright © International Medical Journal Corp. Ltd. All rights reserved

One of the key insights presented in the article is the ongoing debate regarding the relationship between SARS-CoV-2 vaccination and the incidence of Bell's palsy. The authors highlight that while some studies have suggested a potential link, others, including those by Shemer et al., have found no statistically significant association between the BNT162b2 (Pfizer-BioNTech) vaccine and Bell's palsy. This finding is particularly important as it indicates that the incidence of Bell's palsy following vaccination does not exceed the historical rates observed prior to the pandemic, suggesting that the vaccine may not be a contributing factor to the development of this condition ((Ayman Haykal & L. Menkes, 2022)).

Furthermore, the article emphasizes the utility of electrodiagnostic assessments in evaluating infranuclear facial neuropathy, which can aid in predicting clinical outcomes for patients with Bell's palsy. However, the authors note a significant gap in the literature regarding specific electrodiagnostic parameters that could differentiate between Bell's palsy induced by SARS-CoV-2 and that caused by other etiologies. This lack of clarity underscores the need for further research to establish more definitive diagnostic criteria and to better understand the neurophysiological mechanisms at play.

The article titled "The Impact of the COVID-19 Pandemic on Bell’s Palsy and Ramsay-Hunt Syndrome: A Multicenter Retrospective Study" by (Young Kwak et al., 2024) presents significant findings regarding the implications of the COVID-19 pandemic on the incidence of Bell's palsy, particularly in the context of vaccination and infection. The study reveals a notable increase in the average age of diagnosis for Bell's palsy, shifting from 47 to 53 years post-COVID-19, which suggests that older individuals may be at heightened risk due to prevalent comorbidities such as heart disease, hypertension, diabetes, cerebrovascular disease, and respiratory issues.

The authors critically address the contentious relationship between COVID-19 vaccinations and Bell's palsy. They highlight the adverse reactions associated with mRNA COVID-19 vaccines, particularly the robust type 1 interferon response, which they argue may resemble responses seen in patients undergoing type I

Downloaded from The National Medical Journal of Health Science
Copyright © International Medical Journal Corp. Ltd. All rights reserved

interferon therapy. This observation raises the possibility that the immune response triggered by the vaccines could contribute to the occurrence of Bell's palsy. However, the article acknowledges that the association remains debatable, indicating an ongoing need for further research to clarify these relationships.

Moreover, (Young Kwak et al., 2024) provide indirect evidence suggesting a correlation between vaccination in elderly patients and the incidence of facial palsy, which adds a layer of complexity to the discourse on vaccine safety. The potential for direct viral effects from SARS-CoV-2 on facial nerve integrity is also examined, with the authors noting that both direct viral toxicity and immune-mediated mechanisms could contribute to facial nerve damage. This dual perspective emphasizes the necessity of distinguishing between the effects of vaccination and the direct consequences of COVID-19 infection.

CONCLUSION

The reviewed literature provides a comprehensive examination of the relationship between SARS-CoV-2 infection, vaccination, and the incidence of Bell's palsy. Initial studies, such as that by (Mutlu et al., 2021), found no significant increase in Bell's palsy cases during the pandemic, despite the virus's neuroinvasive potential. This finding challenges assumptions of a direct correlation between COVID-19 and Bell's palsy, emphasizing the need for caution in interpreting such associations.

Further investigations, including the case report by (K. Szewczyk et al., 2021), explored bilateral facial palsy as a potential isolated symptom of COVID-19, linking it to Guillain-Barré syndrome and highlighting the immune-mediated mechanisms that may underlie these neurological complications. This perspective was echoed in the population-based study by (Shibli et al., 2021), which noted a higher incidence of Bell's palsy in vaccinated individuals but concluded that the numbers were insufficient to establish a causal relationship.

The literature also indicates that while there are isolated cases of Bell's palsy associated with COVID-19, overall prevalence remains low. For example, (Bhola et al., 2022) reported a mere 0.08% incidence among COVID-19 patients. This

Downloaded from The National Medical Journal of Health Science
Copyright © International Medical Journal Corp. Ltd. All rights reserved

statistic suggests that while some individuals may experience Bell's palsy post-infection, the risk is minimal for the general population.

Case studies, such as the one conducted by (C. Mussatto et al., 2022), reinforced the importance of diagnostic accuracy in attributing Bell's palsy to vaccination. The authors emphasized that the prognosis for Bell's palsy is generally favorable, further supporting the notion that vaccination benefits outweigh potential risks. The review by (Ayman Haykal & L. Menkes, 2022) highlighted the ongoing debate regarding the association between vaccination and Bell's palsy, noting that some studies found no significant links between the two.

The most recent findings presented by (Young Kwak et al., 2024) illustrated an increase in the age of diagnosis for Bell's palsy post-COVID-19, suggesting that older individuals may be at greater risk. This study also raised questions about the immune response triggered by mRNA vaccines and its potential role in facial nerve damage.

In conclusion, the literature reveals a complex interplay between SARS-CoV-2 infection, vaccination, and the incidence of Bell's palsy. While some studies indicate a potential association, the overall risk appears minimal, with the benefits of vaccination significantly outweighing the risks. Ongoing research is essential to clarify these relationships and the underlying mechanisms involved.

DISCLOSURE STATEMENT

- Disclosure Statement : The authors have no conflicts of Interest to declare
- Funding Sources : None
- Acknowledgements : -
- Author Contribution : All authors discussed and contributed the final content for journal submission and publication

REFERENCES

Downloaded from The National Medical Journal of Health Science
Copyright © International Medical Journal Corp. Ltd. All rights reserved

1. Mutlu, A., Tayyar Kalcioglu, M., Yasemin Gunduz, A., Bakici, B., Yilmaz, U., & Cag, Y., 2021. Does the SARS-CoV-2 pandemic really increase the frequency of peripheral facial palsy?. ncbi.nlm.nih.gov
2. K. Szewczyk, A., Skrobas, U., Jamroz-Wiśniewska, A., Mitosek-Szewczyk, K., & Rejdak, K., 2021. Facial Diplegia—Complication or Manifestation of SARS-CoV-2 Infection? A Case Report and Systemic Literature Review. ncbi.nlm.nih.gov
3. Shibli, R., Barnett, O., Abu-Full, Z., Gronich, N., Najjar-Debbiny, R., Doweck, I., Rennert, G., & Saliba, W., 2021. Association between vaccination with the BNT162b2 mRNA COVID-19 vaccine and Bell's palsy: a population-based study. ncbi.nlm.nih.gov
4. Bhola, S., Trisal, J., Thakur, V., Kaur, P., Kulshrestha, S., Kant Bhatia, S., & Kumar, P., 2022. Neurological toll of COVID-19. ncbi.nlm.nih.gov
5. C. Mussatto, C., Sokol, J., & Alapati, N., 2022. Bell's palsy following COVID-19 vaccine administration in HIV+ patient. ncbi.nlm.nih.gov
6. Ayman Haykal, M. & L. Menkes, D., 2022. The clinical neurophysiology of COVID-19-direct infection, long-term sequelae and para-immunization responses: A literature review. ncbi.nlm.nih.gov
7. Young Kwak, M., Yun Lee, H., A Lee, S., Jeong, J., Ho Chung, J., Kim, J., Cho Jun, B., Yeo, S. G., Hoon Kim, S., & Dae Lee, J., 2024. The Impact of the COVID-19 Pandemic on Bell's Palsy and Ramsay-Hunt Syndrome: A Multicenter Retrospective Study. ncbi.nlm.nih.gov

Downloaded from The National Medical Journal of Health Science
Copyright © International Medical Journal Corp. Ltd. All rights reserved